Shield Therapeutics plc (STX.L) Comparison with companies in other sectors?

Shield Therapeutics plc has a share price of 1.04B. You can analyze Shield Therapeutics plc (STX.L) competitors across different market sectors through stock heatmaps.

What are STX.L's NET and operating margins?

Shield Therapeutics plc (STX.L) operating margin is around -0.72, and net profit margin is approximately -0.85 as of the latest reports.

In what way does STX.L's earnings per share (EPS) trend reflect its financial momentum?

Shield Therapeutics plc (STX.L) EPS is -0.02 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Shield Therapeutics plc is -2.25, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Shield Therapeutics plc?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Shield Therapeutics plc like P/E which is -1.65, P/B which is -33.47, and PEG which is -1.65. Compare them with sector averages to evaluate if the stock is priced fairly.

Shield Therapeutics plc

STX.L•LSE

Healthcare

Drug Manufacturers - Specialty & Generic

£4.50

£-0.10(-2.17%)

Shield Therapeutics plc (STX.L) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.02

P/E Ratio

-2.25

ROE

68.33%

Net Margin

-0.85%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$46.88M

Shares OutstandingTotal number of shares issued

$1.04B

Book Value/ShareNet worth per share

$-0.00

Revenue/ShareAnnual revenue per share

$0.03

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.02

Net MarginNet income as percentage of revenue

-84.80%

Operating MarginOperating income as percentage of revenue

-71.73%

ROEReturn on shareholders' equity

6832.78%

ROAReturn on total assets

-46.42%

ROCEReturn on capital employed

-90.79%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.01

Cash/ShareCash and equivalents per share

$0.007

FCF YieldFree cash flow as percentage of market cap

-16.50%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for STX.LFinancial Ratios Analysis details for STX.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for STX.LSector Benchmarking details for STX.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Shield Therapeutics plc Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Shield Therapeutics plc. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Shield Therapeutics plc's unique business strengths and challenges.

Key Financial Metrics for Shield Therapeutics plc

For Shield Therapeutics plc, essential financial indicators include EPS -0.02, PE -2.25, and ROE 68.33. These key ratios reveal insights into Shield Therapeutics plc's profitability, valuation, and operational health. Understanding these metrics enables you to compare Shield Therapeutics plc with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Shield Therapeutics plc

Metrics like Net Margin -84.80% and ROA -46.42% shed light on how well Shield Therapeutics plc is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Shield Therapeutics plc can sustain its operations and continue growing in the future.

Valuation and Market Position of Shield Therapeutics plc

Using ratios such as P/B Ratio -33.47 and PEG Ratio -1.65, investors can assess whether Shield Therapeutics plc is appropriately valued based on its financials and growth potential. These figures, combined with Shield Therapeutics plc's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Shield Therapeutics plc

Financial health indicators, such as Debt/Equity Ratio -20.02 and Cash Flow $-0.01, provide a snapshot of Shield Therapeutics plc's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Shield Therapeutics plc, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Shield Therapeutics plc

Investing in Shield Therapeutics plc based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Shield Therapeutics plc focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;